India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
Depression and suicidality in cancer survivors According to a 2014 study by the World Health Organization in Nepal, 14,300 people die every year due to cancer. According to another report two years later, 30,000 cancer patients are added every year. Officials of concerned agencies say that the number of people who commit suicide due to psychological problems is also high. General Secretary of Cancer Care Society Dr. Sarita Ghimire says that there is no systematic study on the mental condition of cancer patients and their suicide rate in Nepal. However, looking at this situation, his number is alarming. Many people analyze people with cancer from a one-sided angle. However, they did not discuss about their mental condition. Various studies have shown that there is such a problem all over the world. The studies done about their mental problems have shown its terrible condition. According to the data of the World Health Organization, more than 9 million people died from cancer in 201...